CALR and neoplasm: These results suggest that doxorubicin requires the presence of local DCs, which actively phagocyte CRT-positive tumor cells and bona fide cross-present the tumor antigens [4], to recruit host lymphocytes against the tumor and exert a significant pro-immunogenic effect.